Cancer detection with a blood test.

Not Applicable

Recruiting

• Conditions: Prostate cancer; Breast Cancer; Oesophageal cancer; Gastric (stomach) cancer; Lung cancer; Pancreatic cancer; Gallbladder cancer; Biliary tree cancer; Duodenal cancer; Periampullary cancer

• Registration Number: ACTRN12616001138471
• Lead Sponsor: Erin Symonds

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2016-08-22
• Last Update Posted: 8 July 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 1300

Inclusion Criteria

Male or female aged 25 years or more
-Known diagnosis of primary adenocarcinoma of the prostate, breast, lung, pancreas, oesophagus, stomach or digestive tract cancers (of any pathological stage)
-Ability and willingness to undergo venepuncture procedure
-Patients must be capable of providing satisfactory informed consent

Exclusion Criteria

-Unable to provide informed consent.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
The primary outcome will be the levels of methylated BCAT1 and IKZF1 in the blood of people diagnosed with prostate, breast, lung, pancreas oesophageal, stomach cancer, or one of the more rare types of digestive tract cancers, such as, gallbladder, biliary tract, duodenal or periampullary cancer.[ Blood will be collected at a single timepoint for each participant shortly after enrollment. All collected blood samples will have plasma extracted and frozen at -80 degrees. All frozen plasma samples will be stored until the completion of enrollment (approximately 24 months), and then will be analysed for the levels of methylated BCAT1 and IKZF1 and other novel biomarkers.]